Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Achillion Continues To Make Significant Strides In The Fight Against Hepatitis C

Financial analysis of the Achillion hepatitis C drug pipeline; "Achillion is making considerable strides in terms of four drugs currently in its pipeline," Seeking Alpha comments.

Published
15 January 2013
From
Seeking Alpha
Roche Scientists Uncover Unexpected Enzyme Activity in HCV RNA Polymerase

Today, Roche scientists detail the discovery of a new enzyme activity that allows HCV polymerase to remove nucleosides and nucleoside analogues from RNA molecules. This could lead to HCV polymerase counteracting the activity of nucleoside analogs and result in the development of pathways enabling HCV resistance.

Published
11 January 2013
From
Biospace
Nucleotide Polymerase Inhibitors - The Search For A Safe Interferon Free Trial

While the HCV community is waiting in the wings for the first all interferon-sparing therapy to make its way down the pipeline and hopefully all the way to FDA approval, the search for a clinical trial without interferon has become a reality.

Published
10 January 2013
From
HCV New Drugs Research
Idenix May Drop Delayed Hepatitis C Drug for New Versions

Idenix Pharmaceuticals Inc. (IDIX), a developer of hepatitis C drugs, may shelve experimental treatments currently on hold by U.S. regulators and focus on different versions, Chief Executive Officer Ron Renaud said.

Published
10 January 2013
From
Businessweek
Gilead Provides Update on Hepatitis C Development Programs

Sustained Virologic Response Achieved with Oral Regimen of Sofosbuvir, GS-5885 and Ribavirin in 9/9 Null Responder Genotype 1 Hepatitis C Patients; Second Phase 3 Study Evaluating Fixed-dose Combination of Sofosbuvir and GS-5885 to Begin Later this Month.

Published
08 January 2013
From
Gilead press release
Achillion Reports Interim Results on ACH-3102

Enrollment completed in pilot Phase 2a study of ACH-3102 and ribavirin for genotype 1b CC patients; up to 12 weeks of once daily ACH-3102 appears safe and well tolerated with no on-treatment virologic breakthrough observed to date.

Published
08 January 2013
From
Achillion press release
Medivir announces phase III data for Simeprevir demonstrating efficacy and safety in genotype 1 hepatitis C patients

Simeprevir achieved SVR12 rates (viral cure) of 79% to 81% in the three pivotal phase III trials QUEST-1, QUEST-2 and PROMISE in genotype 1 hepatitis C patients. The overall results demonstrate that simeprevir is safe and well tolerated with a safety profile of the simeprevir treatment arms similar to the placebo control. A majority of the patients, 85-93%, were able to stop all treatment after 24 weeks.

Published
20 December 2012
From
Medivir press release
Vertex hepatitis C drug Incivek gets 'black box' warning over possible fatal skin conditions

The FDA says patients taking the pill in combination with two other treatments should stop immediately if they develop a rash that grows worse or comes with symptoms like a fever, diarrhea or mouth sores.

Published
20 December 2012
From
Washington Post
Hepatitis C - First Interferon-Free Regimens Expected to Launch in 2014 in the United States and Europe

The first IFN-free regimens are expected to launch in the United States and Europe by 2014 and, once available, Decision Resources anticipates aggressive and widespread uptake of these therapies in patients who are treatment-naive as well as treatment-experienced.

Published
19 December 2012
From
HCV New Drugs Research
Breaking Up With Gilead Sciences

Eventually, even perpetually bullish Wall Street analysts are going to realize the hepatitis C market is far smaller than current estimates suggest.

Published
17 December 2012
From
The Street

Filter by country